Clinical laboratory tests save costs and lives by enabling early detection and prevention of disease.
Patients with cancers and other conditions are living longer and enjoying better health because of medical revolutions in diagnostic technology.
At its center are genetic and genomic tests that identify the unique genetic profile of individual patients or their disease and allow physicians to tailor treatment to those unique characteristics.
Mainz BioMed (NASDAQ: MYNZ) develops market-ready molecular genetic diagnostic solutions for life-threatening conditions.
Mainz Biomed (NASDAQ: MYNZ) is located just west of Frankfurt in a world-renowned community for advanced DNA & Pharmaceutical research, including the home of vaccine maker BioNTech SE.
The TÜV Rheinland certifies that Mainz Biomed manufactures ColoAlert according to DIN EN ISO 13485. Click here to view certificate.
Mainz Biomed has historical research & development collaborations with major universities, laboratories and governments across Europe.
†
ColoAlert detects tumors better than the standard test (FIT)*
† Approved for sale in EU
*Dollinger MM et al. (2018), ClinLab 64 (10), 1719-1730; internal data comparing ColoAlert to FIT. NOTE: the globally most-used non-invasive test for screening programs. Fecal immunochemical test (FIT) is a screening test for hidden blood in the stool, which can be an early sign of cancer. FIT only detects human blood from the lower intestines. Blood in stool is often a late-stage sign.
** As defined in ColoAlert instructions for use.
1 Colorectal cancer is the second leading cause of cancer death in the US – Cancer.org
2 5-Year Survival rate 91% at Stage A – 2018 American Cancer Society Report
3 Predicted deaths from CRC in USA – Cancer.org.
